Unfortunately, not all MM holdings are success stories, unlike FMG this was disappointingly one, we bought this falling knife way too early, even if it had already more than halved. However the risk / reward feels ok around $5.50 and we’re likely to give this position a little more room into 2022. It might be a long time until it tests our $8.18 entry level but we like the risk / reward around here especially as China makes a few policy tweaks to suit itself of course.
scroll
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Performance update for March, stocks that drove returns & our current positioning
Close
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
MM can still see A2M above $7 in 2022, however view this as a higher risk play
Add To Hit List
Related Q&A
MM’s view on PointsBet (PBH) & a2 Milk (A2M)
Is A2M a buy again?
Reviewing some “losers”
Stocks to lighten as I increase cash
What stocks would we top up here?
Making the tough decision to sell
Question on EVN & A2M
Muted class action on A2M
Tax loss selling in A2 Milk (A2M)
MM thoughts on A2 Milk (A2M) & EML Payments (EML)
What’s our plan with A2 Milk (A2M)
Thoughts on funeral operator IVC, WPL & A2M
Should we just cut A2M?
ALL, CTD, CGC, A2M
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.